Reboxetine: The first selective noradrenaline re-uptake inhibitor

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 771-782

  Kasper, S ^a   El Giamal, N ^a   Hilger, E ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Long term treatment; Noradrenaline; Reboxetine; Social functioning

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; MORPHOLINE DERIVATIVE; NORADRENALIN; REBOXETINE;

AGED; CLINICAL TRIAL; DEPRESSION; HUMAN; METABOLISM; MIDDLE AGED; PHARMACOKINETICS; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL BEHAVIOR;

ADRENERGIC UPTAKE INHIBITORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MIDDLE AGED; MORPHOLINES; NOREPINEPHRINE; PHARMACOKINETICS; SOCIAL BEHAVIOR;

EID: 0034189782     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.771     Document Type: Article

References (39)

1. KESSLER RC, MCGONAGLE KA, ZHAO S et ah Lifetime and 12-month prevalence of DSM-IU-R psychiatric disorders in the United States: results from the
2. National Comorbidity Survey. Arch. Gen. Psycbiat. (1994) 51:8-19.
3. LÉPINE JP, GASTPAR M, MENDLEW1CZ J, TYLEE A ON BEHALF OF THE DEPRES STEERING COMMITTEE: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psycbopbarmacol. (1997) 12:19-29.
4. HIRSCHFELD RMA, MONTGOMERY SA, KELLER M et al: Social functioning in depression: a review. J. Clin. Psycbiat. (2000) (In Press). Comprehensive overview of the relationship between psychosocial impairment and depressive disorders and the efficacy of currently available antidepressants.
5. PAYKEL ES, WEISSMAN MM: Social adjustment and depression. A longitudinal study. Arch. Gen. Psychiat. (1973)28:659-63.
6. KASPER S: Treatment benefits of reboxetine. Int. J. Psycbiat. Clin. Prac. (1999) 3(Suppl. 1):S3-S8. Comprehensive overview of the efficacy of reboxetine for treatment of depression as well as social functioning.
7. RIVA M, BRUNELLO N, ROVESCALLI AC et al.: Effect of reboxetine, a new antidepressant drug, on the central noradrcnergic system: behavioural and biochemical studies./ Drug Dev. (1989) l(4):243-253.
8. STROLIN BENEDETTI M, PELLIZZONI C, POGESSII et al.: Pharmacokinetics of reboxetine cnantiomers in healthy volunteers. Xlltb International Congress of Pharmacology. Montreal, Canada (24-29 July 1994). Abstract no. 13.21.17.
9. DOSTERT P, STROLIN BENEDETTI M, POGESSI I: Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptakc inhibitor. Eur. Neuropbarmacol. (1997) 7(Suppl. 1):S23-S35. Thorough overview of the pharmacokinetics of reboxetine.
10. EDWARDS DMF, PELLIZONI C, BREUL HP et al.: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopbarm. Drug Dispos. (1995) 16:443-460.
11. PELLIZZONI C, STROLIN BENEDETTI M, POGGESI E, FRIGERIO'E, TOON S, LANGLEY SJ: Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect. Pbarmacol. Res. (1995) 31 (Suppl.):4l.
12. FLEISHAKER JC, MUCCI M, PELLIZZONI C, POGGESI I: Absolute bioavailability of reboxetine cnantiomers and effect of gender on pharmacokinetics. Biopharm. Drug Dispos. (1999) 20:53-57.
13. JANNUZZO MG, STROLIN BENEDETTI M, DUCHENE P, DUBINI A, DOSTERT P: Pharmacokinetics of reboxetine in the elderly. Advances in simultaneous pharmacokinctic/pharmacodynamic modelling [abstract]. 2nd International Symposium. Measurement and Kinetics of In vivo Drug Effects. Noordwijkerhout, The Netherlands (14-16 April 1994) 94-96.
14. FIORENTINI F, POGGESI I, JANNUZZO MG, DUCHENE P, STROLIN BENEDETTI M: Pharmacokinetics of reboxetine, a new selective noradrenaline uptake inhibitor, in patients with various degrees of hepatic and renal insufficiency. Pbarmacol. Res. (1997) 35(3):239.
15. NEMEROFF CD, DEVANE CL, POLLOCK BG: Newer antidcprcssants and the cytochrome P450 system. Am. J. Psycbiat. (1996) 153:311-319-
16. MONTGOMERY SA: Reboxetine: addiüonal benefits to the depressed patient. J. Psycbopharmacol. (1997) IKSuppl. 4):S9-S15.
17. MONTGOMERY SA, ANGST J, BULLER R étal.: Report of a consensus meeting. Clinical relevance of response and improvement in psychopharmacology. Eur. Neiiropsychopbarmacol. (1995) 5:531-533-
18. BERZEWSKI H, VAN MOFFAERT M, GAGIANO CA: Efficacy and tolerability of reboxetinc compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neuropsycbopbannacol. (1997) 7(Suppl. 1):S47-S53. Large-scale comparison with the TCA imipramine.
19. MASSANA J, MOLLER HJ, BURROWS GD, MONTENEGRO RM: Reboxetine: a double-blind comparison with fluoxetiiie in major depressive disorder. Int. Clin. Psycbopbarmacol. (1999) 14(2):73-80. Large-scale comparison with the SSRI fluoxetine.
20. ANDERSON IM, TOMENSON BM: The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidcpressants./ Psycbopharmacol. (1994) 8:238-249.
21. KASPER S, FUGER J, MOLLER HJ: Comparative efficacy of antidcprcssants. Drugs (.1992) 43:11-23.
22. KASPER S: Efficacy of antidepressants hi the treatment of severe depression: the plate of mirtazapine./ Clin. Psycbopbarmacol. (1997) 17:10S-28S.
23. NEIRENBERG AA: The treatment of severe depression: is there an efficacy gap between SSRI and TCA antldcpressant generation./ Clin. Psycbiat. (1994) 9:55-59.
24. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Citalopram: clinical effect profile in comparison with clomipramine. A controlled multi-center study. PsycbopbarmacoIogyWSS) 90:131-138.
25. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin rcuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multi-center study./ Affect. Dis. (1990) 18:289-299.
26. MONTGOMERY SA: Managing the severely ill and long-term depressed. Int. J. Psycbiat. Clin. Prac. (1999) 3(Suppl. 1):S13-S17.
27. VERSIANI M, MEHILANE L, GASZNER P, ARNAUDCASTIGLIONI R: Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J. Clin. Psycbiat. (1999) 6
28. BOSC M, DUBINI A, POLIN V: Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur. Neuropsycbopbarmacol. (1997) 7(Suppl. 1):S57-S70.
29. DUBIN A, BOSC M, POLIN V: Do noradrenaline and serotonln differentially affect social motivation and behaviour? Eur. Neuropsychopharmacol. (1997a) TCSuppl. 1):S49-S55. Detailed examination of the effect of two classes of antidepressant on social functioning.
30. DUBINI A, BOSC M, POLIN V: Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning./ Psychopharmacol. (1997W ll(Suppl. -0:517-523. Detailed examination of the effect of two classes of antidepressant on social functioning.
31. KATONA C, BERCOFF E, CHIU E, TACK P, VERSIANI M, WOELK H: Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J. Affect. Dis. (1999) 55(2-3):203-213. Large-scale comparison in elderly patients.
32. HILGER E, WILLEIT M, PRASCHAK-REIDER N et al.: Rcboxctine in seasonal affective disorder. Biol. Psycbiat. (1999) 45:775.
33. EL GIAMAL N, STRNAD A, KASPER S, DE ZWAAN M, BAILER U, LENNK C: Open trial of reboxetine in the treatment of bulimia nervosa (BN) [abstract]. XI World Congress of Psychiatry. Hamburg, Germany. (6-11 August 1999).
34. MUCCI M: Reboxctlne: a review of antideprcssant tolcrability. J. Psychopbarmacol. (1997) IKSuppl. 4):S33-S37. Thorough overview of the tolerability of reboxetine in depressed adult and elderly patients.
35. BALDWIN D, HAWLEYC, SZABADIE étal.: Reboxetine In the treatment of depression: carry clinical experience in the UK. Int.J. Psycbiat, Clin. Prac. (1998) 2:195-201. First report of the utility of reboxetine in general practice.
36. MONTGOMERY SA: Reboxetine: a new antideprcssant therapy. Prescriber (April 1998) 116-119.
37. HINDMARCH I. Effect of antidcprcssants on cognitive and psychomotor function: the lack of effect of reboxetine. Hum. Psychopbannacol. (1998) 13:S21-S27.
38. HERRMANN WM, FUDER H: Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance hi healthy subjects. Hum. Psycbopharmacol. (1998) 13(6):425-433.
39. HOLM KJ: Reboxetine: a review of its use in depression. GVS .Drags (1999) 12(0:65-83. Comprehensive overview of the reboxetine in the treatment of depression.